Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 W 4th Avenue, Vancouver, Canada

Stocktradesmoon Sep. 2 at 4:01 AM

$ABCL

0 · Reply

SocioCobb Sep. 2 at 1:24 AM

$ABCL Yep!

0 · Reply

Stocktradesmoon Sep. 1 at 9:45 PM

$ABCL

0 · Reply

TheBlueFlames Sep. 1 at 9:02 PM

SUNE just got a Merger Agreement, this could be very big. ✅ Float 3.5M ✅ on Breakout watch right now on SUNE! $YJ $ABCL $BOXL $SENS .. :)/

1 · Reply

Stocktradesmoon Sep. 1 at 8:37 PM

$ABCL BAZINGA!!! $11.40’sss After HOURS!! SOMEONE JUST BOUGHT OVER $$500,000!!! That’s a ENORMOUS BUY!! NEWS COMING in the MORNING (PRE-MARKET) SOMEONE KNOWS SOMETHING 😉 LOAD-UP and BUY EVERYTHING you can RIGHT NOW!! I have a feeling we get NEWS TOMORROW MORNING!!! ABCL 575 DATA? Another GIANT PARTNERSHIP? BUYOUT?? More $$$ MONEY?? $13-15’sss. I think we OPEN ABOVE $12 TOMORROW!! MANAGEMENT BOUGHT OVER $2,000,000 OPEN MARKET @ $11’s ONLY FOR 1 REASON BIG NEWS 📰 🗞️ is COMING W/ SHORT at all TIME HIGH 43,000,000 MILLION SHORT the PRICE CAN SQUEEZE to ALL TIME HIGH!!!! Let’s GO!!! I HAVE BEEN RIGHT on ALL my POST’s!! Get in NOW…BUY… or END paying much HIGHER!! NO ONE buys $500,000 after hours for NO REASON!!! 😉

0 · Reply

Stocktradesmoon Sep. 1 at 7:47 PM

$ABCL 👀

1 · Reply

TI7812 Sep. 1 at 7:39 PM

$BHVN $KURA $RVMD $ABCL a few of the many biotechs up on my screens today. like money is rotating into them - well at least its not leaving. Interest rates have zero impact on their futures. so keep playing the game.

0 · Reply

Stocktradesmoon Sep. 1 at 7:39 PM

$ABCL THIS is ALL you NEED to KNOW!!

0 · Reply

desiguy Sep. 1 at 7:37 PM

$ABCL Schroedinger SDGR is up 7% but this is going sideways? 🤨

1 · Reply

Stocktradesmoon Sep. 1 at 7:18 PM

$ABCL BUY NOW!! DO yourself the FAVOR or CATCH yourself buying in the $13’sss. This is a NO BRAINER!! CONSOLIDATION DONE ✅ NICE BIG BUYS ✅ ABCL 575 DATA COMING this QTR ✅ MANAGEMENT BOUGHT OVER $2,000,000 SHARES in the OPEN MARKET in the $11’sss ✅

0 · Reply

AbCellera rises 17.0%

2026-08-25T14:06:36.000Z - 7 days ago

AbCellera rises 10.7%

Aug 13, 2026, 12:05 AM EDT - 20 days ago

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

2026-08-11T20:05:47.000Z - 21 days ago

AbCellera announces $200M common stock, warrants offering

Aug 11, 2026, 4:01 PM EDT - 21 days ago

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2026-08-11T13:35:37.000Z - 21 days ago

AbCellera price target raised to $30 from $12 at Truist

2026-08-10T19:55:32.000Z - 22 days ago

AbCellera price target raised to $25 from $13 at JonesResearch

Aug 10, 2026, 8:00 AM EDT - 22 days ago

AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 22 days ago

AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:23 AM EDT - 22 days ago

This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.

Aug 10, 2026, 7:13 AM EDT - 22 days ago

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

2026-08-10T11:11:27.000Z - 22 days ago

AbCellera announces Phase 1/2 trial of ABCL635 met primary efficacy endpoints

Aug 10, 2026, 7:00 AM EDT - 22 days ago

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

Aug 7, 2026, 4:30 PM EDT - 25 days ago

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

2026-08-06T12:20:50.000Z - 26 days ago

AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:12:02.000Z - 26 days ago

AbCellera price target raised to $12 from $11 at Cantor Fitzgerald

Aug 5, 2026, 5:00 PM EDT - 27 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 27 days ago

AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 27 days ago

AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 27 days ago

AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 4:05 PM EDT - 27 days ago

AbCellera Reports Q2 2026 Business Results

2026-07-29T11:27:06.000Z - 4 weeks ago

AbCellera announces collaboration with Vertex Pharmaceuticals

VRTX

Jul 29, 2026, 7:00 AM EDT - 4 weeks ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

2026-07-09T21:29:02.000Z - 7 weeks ago

3 Under-$10 Stocks with Strong Upside to Watch This Week, According to Analysts

NUVB SERV UBER

Jul 7, 2026, 4:05 PM EDT - 2 months ago

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

2026-07-07T10:35:14.000Z - 2 months ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ

2026-07-06T13:15:29.000Z - 2 months ago

AbCellera apponts Lynn Seely to board of directors

LYEL

Jul 6, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jun 17, 2026, 7:43 AM EDT - 2 months ago

Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

JAZZ

Jun 17, 2026, 7:00 AM EDT - 2 months ago

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

Jun 5, 2026, 9:00 AM EDT - 3 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 4, 2026, 11:40 AM EDT - 3 months ago

AbCellera Biologics Transcript: Jefferies Global Healthcare Conference 2026

May 13, 2026, 8:00 PM EDT - 3 months ago

AbCellera Biologics Transcript: Bank of America Global Healthcare Conference 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 months ago

AbCellera Biologics Slides: Q1 2026

May 11, 2026, 4:05 PM EDT - 4 months ago

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026, 4:05 PM EDT - 4 months ago

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 1, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Slides: Corporate presentation

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 4 months ago

AbCellera Biologics Proxy statement: Proxy filing

Apr 21, 2026, 1:30 PM EDT - 4 months ago

AbCellera Biologics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 20, 2026, 9:00 AM EDT - 4 months ago

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026, 4:05 PM EDT - 5 months ago

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Mar 17, 2026, 4:30 PM EDT - 6 months ago

AbCellera Biologics Transcript: 2026 KeyBanc Capital Markets Healthcare Forum

Mar 4, 2026, 9:50 AM EST - 6 months ago

AbCellera Biologics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 6 months ago

AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 4:05 PM EST - 6 months ago

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026, 4:05 PM EST - 7 months ago

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026, 4:05 PM EST - 7 months ago

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 14, 2026, 6:45 PM EST - 8 months ago

AbCellera Biologics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 7:00 AM EST - 8 months ago

AbCellera Biologics Slides: Corporate presentation

Jan 12, 2026, 9:00 AM EST - 8 months ago

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 9 months ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 9 months ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 3, 2025, 8:00 AM EST - 9 months ago

AbCellera Biologics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:00 AM EST - 10 months ago

AbCellera Biologics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 9:00 AM EST - 10 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 10 months ago

AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 4:05 PM EST - 10 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Sep 29, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 1 year ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 27, 2025, 9:00 AM EDT - 1 year ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation

Jul 7, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 9, 2025, 10:40 AM EDT - 1 year ago

AbCellera Biologics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 30, 2025, 1:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 1 year ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 1 year ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 1 year ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results

May 5, 2025, 9:30 AM EDT - 1 year ago

AbCellera Biologics Transcript: Bloom Burton & Co. Healthcare Investor Conference 2025

Apr 29, 2025, 3:00 PM EDT - 1 year ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing

Apr 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 1 year ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 1 year ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Mar 19, 2025, 1:30 PM EDT - 1 year ago

AbCellera Biologics Transcript: KeyBanc Annual Health Care Forum

Mar 3, 2025, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 1 year ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 3, 2024, 2:30 PM EST - 1 year ago

AbCellera Biologics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 19, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 11:30 AM EST - 1 year ago

AbCellera Biologics Transcript: Stifel 2024 Healthcare Conference

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 2 years ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 4, 2024, 9:00 AM EDT - 2 years ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Stocktradesmoon Sep. 2 at 4:01 AM

$ABCL

0 · Reply

SocioCobb Sep. 2 at 1:24 AM

$ABCL Yep!

0 · Reply

Stocktradesmoon Sep. 1 at 9:45 PM

$ABCL

0 · Reply

TheBlueFlames Sep. 1 at 9:02 PM

SUNE just got a Merger Agreement, this could be very big. ✅ Float 3.5M ✅ on Breakout watch right now on SUNE! $YJ $ABCL $BOXL $SENS .. :)/

1 · Reply

Stocktradesmoon Sep. 1 at 8:37 PM

0 · Reply

Stocktradesmoon Sep. 1 at 7:47 PM

$ABCL 👀

1 · Reply

TI7812 Sep. 1 at 7:39 PM

0 · Reply

Stocktradesmoon Sep. 1 at 7:39 PM

$ABCL THIS is ALL you NEED to KNOW!!

0 · Reply

desiguy Sep. 1 at 7:37 PM

$ABCL Schroedinger SDGR is up 7% but this is going sideways? 🤨

1 · Reply

Stocktradesmoon Sep. 1 at 7:18 PM

0 · Reply

MagicRon_ Sep. 1 at 7:14 PM

$ABCL Terrible day for the bears after that daily reversal candle yesterday - evidence the bears are in control

3 · Reply

Vippizipi Sep. 1 at 6:47 PM

$ABCL big and bigger !

0 · Reply

Stocktradesmoon Sep. 1 at 6:45 PM

$ABCL $ABCL I don’t care how rich you are no one drops over 550/k on something that moved up 77% in just over a month if they aren’t dead serious about their intentions. CARL said ABCL 575 data coming out this Quarter. They MUST KNOW the RESULTS already!! $20’sss by end of SEPTEMBER! MANAGEMENT buying in the $11’sss in the OPEN MARKET!! 🎤

1 · Reply

Stocktradesmoon Sep. 1 at 6:36 PM

$ABCL $ABCL Interesting - CFO buying is always the one I watch closest, they know the numbers. Hayden twice plus multiple directors piling in... those #’s are real conviction. Wonder what they are seeing that we don’t know yet. 🧐

0 · Reply

Stocktradesmoon Sep. 1 at 6:34 PM

$ABCL $ABCL we are too cheap, and they know it…

0 · Reply

Stocktradesmoon Sep. 1 at 6:23 PM

$ABCL ABOUT to GO GREEN!!! $12’ssss!!!

0 · Reply

Stocktradesmoon Sep. 1 at 5:12 PM

$ABCL THE COIL is so SPRUNG we ABOUT to go STRAIGHT to $11.70’sss any minute now. Then $12’sss. This is ABOUT to get GOOD!!! We ABOUT to SKIP through RIGHT to $12’ssss. Very Little resistance in the $12’sss. $13’sss WILL COME FAST!!!!!

1 · Reply

Stocktradesmoon Sep. 1 at 4:41 PM

$ABCL

0 · Reply

Stocktradesmoon Sep. 1 at 4:36 PM

$ABCL 🤡 🤡 🤡

0 · Reply

MagicRon_ Sep. 1 at 4:30 PM

$ABCL LOL the state of you BullTards as if your pocket money is moving a 4 bill MC stock. Just deal with reality this is going back to $5. And get a job, dossers.

3 · Reply

Stocktradesmoon Sep. 1 at 3:55 PM

$ABCL WE ABOUT to TAKE OFF and TACKLE $12’sssss! CONSOLIDATION DONE ✅ HUGE BUY’S COMING in!! A LOT is HAPPENING with ABCL and with ABCL 575 data coming this QUARTER coming from the CEO CARL. With SEVERAL MANAGEMENT BUYING OVER $2,000,000 MILLION dollars in shares in the OPEN MARKET at $11. 1 thing is FOR SURE WE GOING MUCH HIGHER and this is JUST the BEGINNING!!!! BOOM!!! BOOM 💥!! BUY NOW JOIN US for the RIDE!!! ABCL is the #FUTURE of MEDICINE 💊

2 · Reply

Buying_Low_Selling_High Sep. 1 at 3:53 PM

$ABCL Bears are trying but its becoming harder and harder to keep it this low. Huge upwards momentum coming....

0 · Reply

Market Cap	3.52B
Revenue (ttm)	75.13M
Net Income (ttm)	-146.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-194.88%
Debt to Equity Ratio	0.00

Volume	4,251,100
Avg Vol	8,300,594
Day's Range	N/A - N/A
Shares Out	306.61M
Stochastic %K	39%
Beta	1.20
Analysts	Strong Sell
Price Target	$16.12